tetano
Editor, Senior Moderator
Drug Dev Res
. 2021 Jul 29.
doi: 10.1002/ddr.21862. Online ahead of print.
Emerging cases of mucormycosis under COVID-19 pandemic in India: Misuse of antibiotics
Gaurav Gupta[SUP] 1 [/SUP], Roshan S[SUP] 2 [/SUP], Yogendra Singh[SUP] 3 [/SUP], Lakshmi Thangavelu[SUP] 4 [/SUP], Sachin Kumar Singh[SUP] 5 [/SUP], Harish Dureja[SUP] 6 [/SUP], Dinesh Kumar Chellappan[SUP] 7 [/SUP], Kamal Dua[SUP] 8 [/SUP]
Affiliations
Abstract
COVID-19's second wave had a significant impact on India, on May 7, 2021, the largest daily recorded case count was a little more than 4 million, and it has since fallen. Although the number of new cases reported has dropped, during the third week of May 2021, India accounted for about 45% of new cases identified globally and around 34% of deaths. As India maintains its present level of stability, a new urgent threat has emerged in the form of coronavirus-associated mucormycosis. Mucormycosis, an acute and deadly fungal infection caused by Mucorales-related fungal species, is a fungal emergency with a particularly aggressive propensity for contiguous spread, associated with a poor prognosis if not properly and immediately identified, and treated. Mucormycosis, sometimes referred to as the "black fungus," has increased more rapidly in India during the second wave of COVID-19 than during the first wave, with at least 14,872 cases as of May 28, 2021. Uncontrolled diabetic mellitus (DM) and other immunosuppressive diseases such as neutropenia and corticosteroid treatment have traditionally been identified as risk factors for mucormycosis. Therefore, the use of glucocorticoids or high doses of glucocorticoids in mild COVID-19 cases (without hypoxemia) should be avoided. In addition, drugs that target the immune pathway, such as tocilizumab, are not recommended without clear benefits.
Keywords: COVID-19; SARS-CoV-2; black fungus; mucormycosis; steroids.
. 2021 Jul 29.
doi: 10.1002/ddr.21862. Online ahead of print.
Emerging cases of mucormycosis under COVID-19 pandemic in India: Misuse of antibiotics
Gaurav Gupta[SUP] 1 [/SUP], Roshan S[SUP] 2 [/SUP], Yogendra Singh[SUP] 3 [/SUP], Lakshmi Thangavelu[SUP] 4 [/SUP], Sachin Kumar Singh[SUP] 5 [/SUP], Harish Dureja[SUP] 6 [/SUP], Dinesh Kumar Chellappan[SUP] 7 [/SUP], Kamal Dua[SUP] 8 [/SUP]
Affiliations
- PMID: 34323298
- DOI: 10.1002/ddr.21862
Abstract
COVID-19's second wave had a significant impact on India, on May 7, 2021, the largest daily recorded case count was a little more than 4 million, and it has since fallen. Although the number of new cases reported has dropped, during the third week of May 2021, India accounted for about 45% of new cases identified globally and around 34% of deaths. As India maintains its present level of stability, a new urgent threat has emerged in the form of coronavirus-associated mucormycosis. Mucormycosis, an acute and deadly fungal infection caused by Mucorales-related fungal species, is a fungal emergency with a particularly aggressive propensity for contiguous spread, associated with a poor prognosis if not properly and immediately identified, and treated. Mucormycosis, sometimes referred to as the "black fungus," has increased more rapidly in India during the second wave of COVID-19 than during the first wave, with at least 14,872 cases as of May 28, 2021. Uncontrolled diabetic mellitus (DM) and other immunosuppressive diseases such as neutropenia and corticosteroid treatment have traditionally been identified as risk factors for mucormycosis. Therefore, the use of glucocorticoids or high doses of glucocorticoids in mild COVID-19 cases (without hypoxemia) should be avoided. In addition, drugs that target the immune pathway, such as tocilizumab, are not recommended without clear benefits.
Keywords: COVID-19; SARS-CoV-2; black fungus; mucormycosis; steroids.